stockrow
Friday 6 November 2026
Export TXG’s income statement to Excel — free account
10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
59.18
1.12
+1.93%
Follow TXG
Alert me
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 | 6 | 3 | 3 | 7 | 6 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | 10.08 | 43.23 | 48.88 | 10.30 | 16.01 | 3.32 | 3.99 |
P/S ratio |
0.00 | 0.00 | 29.78 | 47.93 | 33.51 | 7.79 | 10.28 | 2.83 | 3.17 |
Altman Z″-Score (non-manufacturers) |
— | (7.91) | 5.15 | 2.02 | 5.26 | 2.65 | 0.47 | 0.28 | 1.63 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.76 |
Beneish M-Score |
— | — | (1.74) | (3.91) | (1.90) | (2.85) | (3.52) | (3.69) | (3.23) |
P/Operating CF |
0.00 | 201.13 | 1,092.84 | (110.03) | 2,831.60 | 293.13 | 246.99 | (256.33) | 49.90 |
P/B ratio |
0.00 | 0.00 | 17.43 | 19.38 | 20.11 | 4.99 | 8.59 | 2.44 | 2.56 |
Price to Tangible BV |
0.00 | 0.00 | 18.39 | 19.98 | 20.87 | 5.17 | 8.84 | 2.51 | 2.79 |
EV/Sales |
0.00 | 0.00 | 28.17 | 45.75 | 32.37 | 7.01 | 9.70 | 2.24 | 2.40 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | (10.66) | 200.06 | (62.75) | (742.93) | (107.71) | (395.02) | 204.98 | 11.33 |
EV/FCF |
0.00 | (7.40) | (853.68) | (53.71) | (129.46) | (21.90) | (92.75) | (203.00) | 11.93 |
Quick Ratio |
2.77 | 2.88 | 7.26 | 6.19 | 6.11 | 4.10 | 3.96 | 4.10 | 3.95 |
Current Ratio |
3.09 | 3.28 | 7.63 | 6.56 | 6.77 | 4.85 | 4.69 | 4.97 | 4.46 |
Net Debt/EBITDA |
(8.60) | 0.33 | 16.78 | 1.32 | 24.52 | 3.21 | 1.75 | 2.61 | 30.49 |
Debt/Assets |
0.00% | 23.87% | 4.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 1.28 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.71 | 2.35 | 0.67 | 0.39 | 0.50 | 0.50 | 0.62 | 0.65 | 0.66 |
Operating CF/Net income |
0.57 | 0.68 | (1.11) | 0.40 | 0.37 | 0.20 | 0.06 | (0.04) | (3.12) |
Capex/Depreciation |
(0.87) | (1.72) | (6.05) | (2.02) | (3.58) | (3.99) | (1.14) | (0.31) | (0.14) |
Interest Coverage |
(22.66) | (45.98) | (9.93) | (317.56) | (60.34) | (352.82) | (8,040.27) | (48,639.75) | — |
| 11.27% | 67.56% | (31.24%) | (93.64%) | (7.48%) | (20.45%) | (32.98%) | (25.17%) | (5.78%) | |
| (18.76%) | (180.97%) | (8.56%) | (70.70%) | (5.98%) | (16.21%) | (25.59%) | (19.39%) | (4.44%) | |
ROIC |
(9.49%) | 0.00% | (74.54%) | (566.77%) | (14.26%) | (28.13%) | (47.06%) | (38.39%) | (13.97%) |
Return on Tangible Assets |
(35.40%) | (132.33%) | (6.70%) | (74.44%) | (7.22%) | (20.92%) | (34.08%) | (25.39%) | (5.75%) |
Average Days of Receivables |
66.75 | 70.07 | 49.54 | 62.54 | 63.44 | 73.66 | 67.74 | 52.87 | 46.84 |
Research and Development Expense of Revenue |
45.25% | 32.49% | 33.79% | 41.28% | 43.17% | 51.45% | 43.69% | 43.34% | 37.12% |
Selling, General and Administrative Expense of Revenue |
65.75% | 60.10% | 53.21% | 67.70% | 52.51% | 57.76% | 55.49% | 56.38% | 49.18% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.04 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.06 |
Share Based Compensation of Revenue |
2.34% | 1.82% | 5.42% | 16.27% | 19.56% | 26.50% | 26.98% | 23.04% | 16.97% |
Graham Net Nets |
0.00 | 0.13 | 0.04 | 0.04 | 0.03 | 0.10 | 0.06 | 0.22 | 0.22 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(1.74%) | (2.62%) | (1.76%) | (3.64%) | (0.35%) | (4.16%) | (4.00%) | (10.58%) | (2.15%) |
Free Cash Flow Yield |
0.00% | (12.94%) | (0.11%) | (1.78%) | (0.75%) | (4.11%) | (1.02%) | (0.39%) | 6.35% |
Revenue per Share |
6.13 | 10.93 | 6.29 | 2.95 | 4.44 | 4.54 | 5.28 | 5.07 | 5.15 |
Operating CF per Share |
(0.92) | (5.71) | 0.89 | (2.15) | (0.19) | (0.30) | (0.13) | 0.06 | 1.09 |
Capex per Share |
(0.32) | (0.50) | (1.09) | (0.38) | (0.92) | (1.16) | (0.42) | (0.11) | (0.05) |
Free Cash Flow per Share |
(1.25) | (6.21) | (0.21) | (2.53) | (1.11) | (1.45) | (0.55) | (0.06) | 1.04 |
Cash per Share |
4.14 | 4.86 | 10.85 | 6.72 | 5.33 | 3.80 | 3.32 | 3.27 | 4.20 |
Shareholders Equity per Share |
0.00 | 1.74 | 10.75 | 7.31 | 7.41 | 7.08 | 6.32 | 5.90 | 6.38 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 1.74 | 10.75 | 7.31 | 7.41 | 7.08 | 6.32 | 5.90 | 6.38 |
Free Cash Flow |
(14.45) | (83.12) | (8.14) | (256.29) | (122.65) | (165.27) | (64.72) | (6.73) | 130.12 |
Working Capital |
46.00 | 73.87 | 417.79 | 656.24 | 637.23 | 504.08 | 468.86 | 466.75 | 531.00 |
Capital Expenditures |
(3.76) | (6.71) | (42.77) | (38.39) | (101.28) | (131.66) | (49.52) | (13.39) | (5.93) |
Net Current Asset Value |
68.00 | 5.18 | 295.00 | 584.10 | 546.33 | 411.80 | 371.92 | 375.89 | 439.41 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.05 | 0.05 | 0.17 | 0.13 | 0.21 | 0.26 | 0.08 | 0.02 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.62 | 0.35 | 0.14 | 0.26 | 0.17 | 0.11 | 0.16 | 0.17 | 0.19 |
Cash ROIC |
(6.66%) | (70.43%) | (0.93%) | (18.06%) | (8.72%) | (13.35%) | (5.73%) | (0.61%) | 9.86% |
Accounts Receivable Turnover |
3.47 | 7.12 | 8.00 | 7.07 | 7.19 | 5.45 | 5.65 | 6.01 | 7.52 |
Accounts Payable Turnover |
1.51 | 4.16 | 5.59 | 6.59 | 6.72 | 6.18 | 11.22 | 13.71 | 15.52 |
Inventory Turnover |
1.51 | 4.22 | 5.12 | 2.59 | 1.65 | 1.70 | 2.70 | 2.50 | 2.85 |
Average Days of Payables |
172.82 | 111.97 | 77.91 | 29.40 | 85.48 | 65.49 | 27.43 | 24.00 | 23.36 |
Days of Inventory on Hand |
172.82 | 109.14 | 91.32 | 187.03 | 295.42 | 247.49 | 128.47 | 154.53 | 103.37 |
Average Receivables |
20.50 | 20.54 | 30.73 | 42.29 | 68.23 | 94.73 | 109.52 | 101.65 | 85.48 |
Average Payables |
7.00 | 6.90 | 10.91 | 8.87 | 11.03 | 19.48 | 18.67 | 14.32 | 12.82 |
Average Inventory |
7.00 | 6.79 | 11.92 | 22.61 | 44.96 | 70.80 | 77.67 | 78.41 | 69.72 |
Average Assets |
100.00 | 62.16 | 365.12 | 767.63 | 974.08 | 1,023.90 | 997.06 | 941.89 | 980.00 |
Average Common Equity |
(166.50) | (166.49) | 100.05 | 579.58 | 778.32 | 811.66 | 773.39 | 725.59 | 753.23 |
Columns are period end dates · fundamentals updated 6 Nov 2026